Nektar Therapeutics (NKTR)
1.285
-0.04
(-2.65%)
USD |
NASDAQ |
Apr 19, 11:26
Nektar Therapeutics Revenue (TTM): 90.12M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 90.12M |
| September 30, 2023 | 88.26M |
| June 30, 2023 | 87.74M |
| March 31, 2023 | 88.83M |
| December 31, 2022 | 92.06M |
| September 30, 2022 | 95.04M |
| June 30, 2022 | 96.34M |
| March 31, 2022 | 103.08M |
| December 31, 2021 | 101.91M |
| September 30, 2021 | 100.36M |
| June 30, 2021 | 105.47M |
| March 31, 2021 | 125.99M |
| December 31, 2020 | 152.92M |
| September 30, 2020 | 163.32M |
| June 30, 2020 | 162.50M |
| March 31, 2020 | 136.97M |
| December 31, 2019 | 114.62M |
| September 30, 2019 | 120.58M |
| June 30, 2019 | 119.12M |
| March 31, 2019 | 1.184B |
| December 31, 2018 | 1.193B |
| September 30, 2018 | 1.249B |
| June 30, 2018 | 1.374B |
| March 31, 2018 | 321.00M |
| December 31, 2017 | 307.71M |
| Date | Value |
|---|---|
| September 30, 2017 | 249.70M |
| June 30, 2017 | 133.10M |
| March 31, 2017 | 131.28M |
| December 31, 2016 | 165.44M |
| September 30, 2016 | 167.36M |
| June 30, 2016 | 190.97M |
| March 31, 2016 | 180.86M |
| December 31, 2015 | 230.78M |
| September 30, 2015 | 210.97M |
| June 30, 2015 | 283.88M |
| March 31, 2015 | 289.74M |
| December 31, 2014 | 200.71M |
| September 30, 2014 | 212.30M |
| June 30, 2014 | 140.34M |
| March 31, 2014 | 145.69M |
| December 31, 2013 | 148.92M |
| September 30, 2013 | 138.92M |
| June 30, 2013 | 96.42M |
| March 31, 2013 | 86.25M |
| December 31, 2012 | 81.19M |
| September 30, 2012 | 75.83M |
| June 30, 2012 | 84.48M |
| March 31, 2012 | 78.13M |
| December 31, 2011 | 71.48M |
| September 30, 2011 | 101.01M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
87.74M
Minimum
Jun 2023
163.32M
Maximum
Sep 2020
112.91M
Average
103.08M
Median
Mar 2022
Revenue (TTM) Benchmarks
| Stereotaxis Inc | 26.77M |
| Vanda Pharmaceuticals Inc | 192.64M |
| Cara Therapeutics Inc | 20.97M |
| Marinus Pharmaceuticals Inc | 30.99M |
| DiaMedica Therapeutics Inc | -- |